Financial Data and Key Metrics Changes - The company reported a full-year revenue growth of 6% and adjusted diluted earnings per share growth of 7% for 2025, with free cash flow of $2.1 billion, representing about 100% of adjusted net income [4][24] - Fourth quarter revenue was $4,364 million, up 10.3% on a reported basis and 8.1% at constant currency, with adjusted diluted EPS of $3.42, an increase of 9.6% year-over-year [20][23] - Full-year revenue reached $16.31 billion, up 5.9% reported and 4.8% at constant currency [21] Business Line Data and Key Metrics Changes - Technology Analytics Solutions revenue for Q4 was $1,821 million, up 9.8% reported and 7.1% at constant currency [20] - R&D Solutions revenue for Q4 was $2,333 million, up 9.1% reported and 8.2% at constant currency [20] - Contract Sales and Medical Solutions (CSMS) revenue for Q4 was $210 million, an increase of 18.6% reported and 15.3% at constant currency [20] Market Data and Key Metrics Changes - The backlog reached a new record of $32.7 billion at the end of Q4, growing 5.3% compared to the prior year [9][23] - Qualified pipeline was about 10% higher year-over-year, with double-digit growth in RFP flow across all segments [9] Company Strategy and Development Direction - The company is focusing on simplifying its organization into two reporting segments: Commercial Solutions and R&D Solutions, to better align with evolving market demands [14][15] - A strategic collaboration with Amazon Web Services was announced to accelerate digital transformation in the industry [10] - The company is investing in AI-driven innovations and has deployed over 150 AI agents across various use cases [37][40] Management's Comments on Operating Environment and Future Outlook - Management noted that the macroeconomic environment led to slower customer decision-making but indicated that demand indicators became more favorable as the year progressed [4][5] - The company expects revenue for 2026 to be between $17.15 billion and $17.35 billion, with adjusted EBITDA guidance of $3.975 billion to $4.025 billion [25][26] Other Important Information - The company was recognized for its AI leadership, being ranked number one for generative AI leadership in life sciences by Everest Group [11] - The CFO, Ron Bruehlman, is transitioning to a senior advisory role after a long tenure [16][17] Q&A Session Summary Question: Concerns about AI disrupting established businesses - Management clarified that AI is viewed as an opportunity rather than a challenge, emphasizing the company's proprietary data and domain expertise as key differentiators [31][32][40] Question: Value and driver of the Cedar Gate acquisition - The acquisition is expected to enhance the company's payer provider analytics capabilities, with Cedar Gate contributing approximately $140 million in revenue and $36-37 million in adjusted EBITDA for 2025 [46][47] Question: Impact of AI on trial efficiency and demand dynamics - Management stated that AI is expected to improve trial efficiency but does not foresee a reduction in the number of trials conducted by large pharma clients [68][70]

分组1 - IQVIA Holdings reported quarterly earnings of $3.42 per share, exceeding the Zacks Consensus Estimate of $3.4 per share, and showing an increase from $3.12 per share a year ago, representing an earnings surprise of +0.50% [1] - The company achieved revenues of $4.36 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.83%, and up from $3.96 billion in the same quarter last year [2] - IQVIA has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market, losing about 10.2% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.95 on revenues of $4.04 billion, and for the current fiscal year, it is $12.93 on revenues of $17.03 billion [7] 分组3 - The Medical - Instruments industry, to which IQVIA belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for IQVIA was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

Group 1 - The core viewpoint of the article is that IQVIA Holdings has forecasted annual profit below Wall Street expectations due to increased interest costs, despite strong fourth-quarter results [1] Group 2 - IQVIA Holdings is a healthcare data and clinical research provider [1] - The company reported strong performance in the fourth quarter, but this was overshadowed by concerns regarding higher interest expenses [1]

Q4 2025 Earnings Call February 5, 2026 © 2026. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. IQVIA Template (V4.0.0) 100% 50% 75% 25% Bright Blue Indigo Bright Teal Bright Green Emerald 5% Charcoal Red Legal 2 IQVIA Template (V2.1.0) 100% 50% 75% 25% This presentation should be viewed in conjunction with IQVIA's Q4 2025 earnings call Safe Harbor Statement for Forward-Looking Statements This presentation contains "fo ...

Financial Performance - Fourth-quarter revenue was $4,364 million, an increase of 10.3% year-over-year, and full-year revenue reached $16,310 million, growing 5.9%[4][8] - GAAP Net Income for the fourth quarter was $514 million, up 17.6% year-over-year, and for the full year, it was $1,360 million, down 0.9%[6][9] - Adjusted EBITDA for the fourth quarter was $1,046 million, increasing 5.0% year-over-year, and for the full year, it was $3,788 million, up 2.8%[6][9] - Adjusted Diluted Earnings per Share for the fourth quarter was $3.42, up 9.6% year-over-year, and for the full year, it was $11.92, up 7.1%[6][9] - Total revenues for the year ended December 31, 2025, reached $16,310 million, an increase of 5.9% from $15,405 million in 2024[36] Cash Flow and Debt - Operating Cash Flow for the fourth quarter was $735 million, bringing full-year Operating Cash Flow to $2,654 million[10] - Free Cash Flow for the fourth quarter was $561 million, resulting in full-year Free Cash Flow of $2,051 million, representing 99% of Adjusted Net Income[10] - Net cash provided by operating activities for 2025 was $2,654 million, slightly down from $2,716 million in 2024[27] - Net cash provided by operating activities for Q4 2025 was $735 million, down from $885 million in Q4 2024, resulting in a decrease of 16.9%[32] - Free cash flow for the twelve months ended December 31, 2025, was $2,051 million, a decline of 3.0% compared to $2,114 million in 2024[32] - The company’s long-term debt increased to $13,884 million in 2025 from $12,838 million in 2024, reflecting an 8.1% increase[25] - Gross debt as of December 31, 2025, was $15,724 million, with a gross leverage ratio of 4.15x based on adjusted EBITDA of $3,788 million[34] - Net debt as of December 31, 2025, was $13,744 million, resulting in a net leverage ratio of 3.63x[34] Operational Metrics - R&D Solutions contracted backlog as of December 31, 2025, was $32.7 billion, growing 5.3% year-over-year, with an expected revenue conversion of approximately $8.3 billion in the next twelve months[5][7] - The fourth-quarter book-to-bill ratio was 1.18x, resulting in a trailing-twelve-month book-to-bill ratio of 1.12x[5][7] - Revenues from Commercial Solutions for Q4 2025 were $1,844 million, up 10.9% from $1,662 million in Q4 2024[36] - Research & Development Solutions generated $2,520 million in revenue for Q4 2025, compared to $2,296 million in Q4 2024, reflecting a growth of 9.8%[36] Guidance and Future Outlook - Full-year 2026 revenue guidance is projected to be between $17,150 million and $17,350 million, with Adjusted EBITDA expected between $3,975 million and $4,025 million[12][13] - The company continues to invest in property, equipment, and software, with acquisitions totaling $603 million for the year ended December 31, 2025[32] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[36] Other Financial Information - The company repurchased $212 million of its common stock in the fourth quarter, totaling $1,244 million for the full year[11] - The company incurred restructuring costs of $105 million for the year 2025, compared to $67 million in 2024[23] - Total assets increased to $29,944 million in 2025, up from $26,899 million in 2024, marking an 11.4% growth[25] - Cash and cash equivalents at the end of 2025 were $1,980 million, an increase from $1,702 million at the end of 2024[27] - The company reported a total current liabilities of $8,338 million in 2025, compared to $6,957 million in 2024, indicating a 19.8% rise[25] - Basic earnings per share for 2025 were $7.91, up from $7.57 in 2024, representing a 4.5% increase[23]

Core Insights - IQVIA Holdings Inc. (IQV) is scheduled to release its fourth-quarter 2025 results on February 5, with a history of surpassing earnings estimates, averaging a surprise of 1.6% over the last four quarters [1] Revenue Expectations - The Zacks Consensus Estimate for IQV's revenues is $4.2 billion, reflecting a year-over-year growth of 7.2% [2] - The Technology & Analytics (TAS) segment is expected to generate revenues of $1.8 billion, indicating a 6.9% increase from the previous year, driven by drug launches and a strong commercial portfolio [2] - For the Research & Development segment, revenues are estimated at $2.3 billion, suggesting a 7.7% year-over-year increase, supported by a 20% growth in Request for Proposals in Q3 2025 [3] - The Contract Sales & Medical segment's revenues are projected at $193.2 million, representing a 9.1% increase from the prior year, attributed to large multi-year engagements [4] Geographic Revenue Breakdown - Revenue from the Americas is estimated at $2 billion, indicating an 8.1% increase year-over-year [5] - For Europe and Asia, the revenue estimate stands at $1.3 billion, suggesting a 3.8% rise from the previous year [5] - Asia-Pacific revenues are projected to reach $882.6 million, reflecting a 9.4% year-over-year growth [5] Earnings Per Share - The consensus estimate for earnings per share is $3.4, indicating a 9% growth compared to the previous year [5] Earnings Prediction Model - The current model does not predict a definitive earnings beat for IQVIA, with an Earnings ESP of 0.00% and a Zacks Rank of 2 (Buy) [6]

Investment Rating - The report does not explicitly provide an investment rating for the biosimilar industry in Europe. Core Insights - The report highlights the ongoing importance of biosimilars in the European healthcare system, emphasizing their role in cost savings for payers, creating space for innovation, and expanding patient access to biologics since the first biosimilar was launched in 2006 [5][11]. - It presents new observations regarding the market status in 2025 and a simplified set of key performance indicators (KPIs) to monitor the impact of biosimilars across 23 European markets [6][7]. - The report indicates that the biosimilar market is maturing, with growth rates aligning more closely with other segments of the pharmaceutical market, reflecting a growth rate of approximately 11% [12]. Summary by Sections Introduction - The report builds on previous publications and provides forward-looking insights into the opportunities and challenges facing the European biosimilar competition [4]. Pipeline - The analysis indicates that by 2032, around 100 biologics will lose exclusivity in Europe, with 79% currently lacking any biosimilar in development, leading to an increase in biosimilar gaps [26][28]. Commercial Attractiveness - Regulatory simplifications by the European Medicines Agency (EMA) are expected to reduce development costs and timelines for biosimilars, although they may not fully address existing biosimilar gaps [37][38]. International Competitiveness - Europe remains a leader in the biosimilar market, with a market size that is 55% larger than that of the U.S. and significantly exceeds that of China [50][51]. Access Inequality - There is a persistent disparity in access to biologics between Western and Eastern Europe, with patients in Western Europe receiving 35% more treatment days compared to those in Eastern Europe [59][64]. Advanced Planning - The report emphasizes the need for advanced indicators to support understanding of the future impacts of biosimilar competition, highlighting the importance of monitoring pipeline activities and market dynamics [25][28].

Report Summary 1. Report Industry Investment Rating - Not provided in the content. 2. Core Viewpoints - The RDEP represents a significant evolution in FDA's approach to ultra - rare disease drug development, emphasizing scientific flexibility and innovation while maintaining strict evidence standards [22]. - Success under the RDEP depends on strategic integration of real - world evidence, strong confirmatory evidence, and careful cooperation with regulatory agencies [24]. 3. Summary by Related Catalog RDEP Introduction - In September 2025, the FDA released the Rare Disease Evidence Principles (RDEP), a new review process for ultra - rare, genetically - defined diseases, aiming to provide more clarity and predictability [3]. - RDEP is built on the precedent of the FDA's 2023 draft guidance, using a well - controlled clinical study to prove effectiveness and provide confirmatory evidence [4]. Comparison with Existing Pathways - RDEP formalizes the FDA's previous practices in rare - disease approvals, and it supplements existing mechanisms like accelerated approval, orphan drug designation, and RDEA pilot by clarifying evidence expectations [7][8]. Eligibility for RDEP - RDEP aims to support therapy developers for diseases that meet all of the following conditions: a sponsor can prove a well - controlled study with strong evidence to establish effectiveness; the disease is caused by a known congenital genetic defect; the situation is critical, rapidly progressing, and there is no disease - modifying treatment; and fewer than 1000 patients in the US are affected [8]. Role of RWE - Before accessing the RDEP process, RWE can be used to confirm the ultra - rare prevalence threshold of a disease by combining medical claims, EHRs, genomic databases, and patient registries, and AI - driven analysis can further refine these estimates [11][12]. - Once in the RDEP process, RWE plays a core role in natural history studies, patient registries, external comparator arms, and expanded access data and case reports [15]. Patient - Centered Development - In ultra - rare diseases, patient - centered drug development is crucial, and natural history studies and registries, especially those co - designed with advocacy groups, help identify important functional changes for patients and caregivers [18]. Time Considerations - Before starting a critical trial, sponsors should submit an application to their existing IND for each protocol they want to be reviewed under RDEP, including reasonable evidence to meet the inclusion criteria and prove the drug's safety and effectiveness [21]. Conclusion - RDEP provides a customized pathway for programs less likely to meet traditional requirements, and cooperation is key to accelerating treatment for patients in need [23][24].

Core Insights - Medical device companies are transitioning from hardware vendors to data-driven service organizations, creating new revenue opportunities and enhancing value for healthcare providers through advanced analytics and AI integration [1][2]. Group 1: Medtronic - Medtronic is leveraging data analytics and AI to improve clinical outcomes and operational insights, integrating these technologies into its product ecosystem [7][9]. - The company uses AI to provide procedure-level insights and personalized care, enhancing treatment plans and patient outcomes [8][9]. - Medtronic's investment in analytics infrastructure has unified data sources, improving decision-making and operational efficiency across its workforce [11][12]. - The integration of analytics into device offerings is expected to generate recurring revenue streams, moving beyond traditional hardware sales [13][14]. Group 2: IQVIA - IQVIA operates as a data-centric healthcare technology company, monetizing clinical data and analytics services for life sciences companies [15][21]. - The Connected Intelligence platform merges healthcare data with analytics to support strategic decisions in clinical development and commercialization [16][20]. - IQVIA's analytics capabilities include real-time data processing and AI-powered insights, which are essential for product development and market access strategies [19][20]. - The company has an expected revenue growth rate of 5.4% and an earnings growth rate of 8.4% for the current year [22]. Group 3: GE HealthCare - GE HealthCare combines its diagnostic imaging legacy with enterprise data infrastructure to enhance patient data management and insights [23][24]. - The Enterprise Data Hub consolidates various data sources, providing actionable insights that improve operational efficiency and clinical decision-making [24][26]. - GE HealthCare's analytics solutions are offered through subscription models, generating recurring revenue alongside traditional equipment sales [27][28]. - The company has an expected revenue growth rate of 4.3% and an earnings growth rate of 8.1% for the current year [28].

Core Insights - IQVIA Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry, headquartered in Durham, North Carolina [1] - The company has a market capitalization of $41.28 billion and operates across several countries, assisting pharmaceutical, biotechnology, and medical device companies through its core segments [2] Financial Performance - Analysts expect IQVIA to report a profit of $3.13 per share on a diluted basis for Q4 fiscal 2025, representing a year-over-year increase of 7.9% [4] - For the full fiscal year 2025, diluted EPS is expected to grow by 5.3% annually to $10.79, followed by an 8.7% improvement to $11.73 in fiscal 2026 [4] Stock Performance - Over the past 52 weeks, IQVIA's stock has gained 18.5%, while over the past six months, it has gained 48% [5] - In comparison, the broader S&P 500 Index has increased by 19.7% and 11.5% over the same periods, indicating that IQVIA has underperformed the broader market over the past year but outperformed over the past six months [5] Sector Comparison - The State Street Health Care Select Sector SPDR ETF has gained 12.7% over the past 52 weeks and 16.4% over the past six months, showing that IQVIA has outperformed its sector during these periods [6] Strategic Partnerships - Last month, IQVIA announced a partnership with Amazon Web Services (AWS), designating AWS as its Preferred Agentic Cloud Provider, which includes the provision of IQVIA's AI platform on AWS to enhance healthcare analytics [7]